Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- WCC -15.1%, TDC -13.4%, HAS -10.3%, INMD -9.4%, SHOP -9.3%, DDOG -8.9%, CDNS -8%, BHF -6.5%, ANET -6.4%, LSCC -6.3%, BLKB -6.2%, ZTS -4.7%, WSO -4.5%, BIIB -4.4%, DNUT -4.3%, JHX -3%, GT -2.8%, HPP -2.6%, MAR -2.2%, MCO -1.8%, CAR -1.3%, MEDP -1.2%, BRX -1.1%
Other news:
- GTHX -42.9% (continuing Phase 3 Trial of Trilaciclib)
- ELTK -15.2% (prices offering of 625K ordinary shares at $16.00 per share)
- MUX -5.6% (production and guidance report)
- BIIB -4.4% (EC authorizes SKYCLARYS for treatment of Friedreich's ataxia)
- GTES -4.3% (stock offering)
- RSKD -2.3% (has undertaken certain actions to reduce operating expenses by initiating a reduction in force that is expected to impact approximately 6% of the Company's workforce)
- STRL -2% (CFO to retire)
Analyst comments:
- PLCE -10.7% (downgraded to Sell from Neutral at B. Riley Securities)
- NAPA -4.9% (downgraded to Underperform from Neutral at BofA Securities)
- NET -3% (downgraded to Hold from Buy at DZ Bank)
- PYPL -1.5% (downgraded to Neutral from Outperform at Daiwa Securities)
- UAL -0.5% (downgraded to Neutral from Buy at Redburn Atlantic)